•Outlook resubmits wet AMD BLA for bevacizumab after FDA appeal win •Leadership watch: Optivate, TVC, Ocuco name new executives•National Academy of Opticianry and United Opticians Association kick-start potential merger•Lexitas acquires Erie Retina Research to expand ophthalmic trials•NeuroVision expands retinal imaging-based neurodegenerative disease detection with new acquisition •Outlook resubmits wet AMD BLA for bevacizumab after FDA appeal win •Leadership watch: Optivate, TVC, Ocuco name new executives•National Academy of Opticianry and United Opticians Association kick-start potential merger•Lexitas acquires Erie Retina Research to expand ophthalmic trials•NeuroVision expands retinal imaging-based neurodegenerative disease detection with new acquisition
HEADLINES
FEATURED
While OCS-01 was well-tolerated, the DIAMOND program did not meet either outcome measures; company will not seek an FDA NDA filing.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
